Unicycive Therapeutics (UNCY) Projected to Announce Earnings on Wednesday

Unicycive Therapeutics (NASDAQ:UNCY) will likely be issuing its Q3 2026 results before the market opens on Wednesday, November 11th. Analysts expect Unicycive Therapeutics to announce earnings of ($0.33) per share and revenue of $0.90 million for the quarter. Investors may visit the company’s upcoming Q3 2026 earnings report page for the latest details on the call scheduled for Thursday, November 12, 2026 at 9:30 AM ET.

Unicycive Therapeutics (NASDAQ:UNCY) last released its earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, topping the consensus estimate of ($0.47) by $0.41. On average, analysts expect Unicycive Therapeutics to post ($1.16) EPS for the current fiscal year and $1.44 EPS for the next fiscal year.

Unicycive Therapeutics Stock Up 3.8%

Shares of UNCY opened at $3.73 on Wednesday. The firm has a market cap of $103.77 million, a PE ratio of -2.12 and a beta of 1.91. The company’s fifty day moving average is $4.46 and its two-hundred day moving average is $6.06. Unicycive Therapeutics has a fifty-two week low of $3.33 and a fifty-two week high of $8.74.

Analyst Ratings Changes

Several equities research analysts recently issued reports on the company. Wall Street Zen raised Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research report on Saturday, August 15th. Weiss Ratings reissued a “sell (d-)” rating on shares of Unicycive Therapeutics in a report on Friday, September 4th. Benchmark reaffirmed a “speculative buy” rating and issued a $15.00 price objective (up from $13.00) on shares of Unicycive Therapeutics in a report on Thursday, August 20th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price objective (down from $22.00) on shares of Unicycive Therapeutics in a research report on Wednesday, August 12th. Finally, Zacks Research raised shares of Unicycive Therapeutics from a “strong sell” rating to a “hold” rating in a research note on Wednesday, August 19th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $18.25.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc (NASDAQ: UNCY) is a clinical-stage biotechnology company focused on developing treatments for kidney disease and related metabolic complications. The company’s primary focus is hyperphosphatemia, an excess of phosphate in the blood that commonly affects people with chronic kidney disease, particularly those receiving dialysis.

Unicycive’s lead product candidate is oxylanthanum carbonate (OLC), an investigational, orally administered phosphate binder designed to bind dietary phosphate in the gastrointestinal tract and reduce its absorption into the bloodstream.